{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_8288110_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"175-894-718-940-379","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11797,"type":"PATENT","title":"Queen's University at Kingston Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5666,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8427,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: queen* AND univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1261
Search Applicants and Owners separately: queen* AND univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1261
detecting one or both of the presence and amount of one or more biomarkers in a biological sample from the subject,\n
wherein at least one of the biomarkers is a peptide selected from SEQ ID NOs: 1-6, 8-13, 15, 20, and 22; and\n
classifying the subject as likely to have ovarian cancer if\n
(a) the amount of the peptide selected from SEQ ID NOs: 1, 2, 4, 8, 9, 10, 11, and 12 is decreased in the biological sample as compared to a non-ovarian cancer reference amount of the biomarker; or\n
(b) the amount of the peptide selected from SEQ ID NOs: 3, 5, 6, 13, 15, 20, and 22 is increased in biological sample as compared to a non-ovarian cancer reference amount of the biomarker."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein an increase in the amount of a biomarker peptide selected from SEQ ID NOs: 3, 5, 6, 13, 15, 20, and 22 in the biological sample as compared to the non-ovarian cancer reference amount of the biomarker peptide indicates that the subject has an ovarian cancer."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the amount of the biomarker peptide in the biological sample is at least two-fold higher than the non-ovarian cancer reference amount of the biomarker peptide."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein a decrease in the amount of a biomarker peptide selected from SEQ ID NOs: 1, 2, 4, 8, 9, 10, 11, and 12 in the biological sample as compared to the non-ovarian cancer reference amount of the biomarker peptide indicates that the subject has an ovarian cancer."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 4, wherein the amount of the biomarker peptide in the biological sample is at least two-fold lower than the non-ovarian cancer reference amount of the biomarker peptide."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, comprising classifying the subject as likely to have an ovarian cancer of a type selected from the group consisting of a serous cystoma, a mucinous cystoma, an endometroid tumor, and a clear cell tumor."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, comprising classifying the subject as likely to have an ovarian cancer at a stage selected from the group consisting of Stage I, Stage IA, Stage IB, Stage IC, Stage II, Stage IIA, Stage IIB, Stage IIC, Stage III, Stage IIIA, Stage IIIB, Stage IIIC, and Stage IV."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising obtaining the biological sample from the subject."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the subject is a human."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method claim 1, wherein the non-ovarian cancer reference amount of the biomarker peptide is an amount of the biomarker peptide in a biological sample from a subject that does not have an ovarian cancer."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the biological sample comprises serum."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the detecting comprises mass spectrometry."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the one or more biomarkers comprise at least four of the biomarker peptides."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the one or more biomarkers comprise at least five of the biomarker peptides."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14, wherein the at least five biomarker peptides are selected from the group consisting of SEQ ID NOS: 2, 3, 4, 5, and 6."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the one or more biomarkers comprise at least seven of the biomarker peptides."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 16, wherein the at least seven biomarker peptides are selected from the group consisting of SEQ ID NOS: 8, 15, 2, 3, 4, 5, and 6."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the one or more biomarkers comprise at least nine of the biomarker peptides."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the at least nine biomarker peptides are selected from the group consisting of SEQ ID NOS: 9, 8, 12, 10, 11, 15, 22, 13, and 20."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising detecting one or both of the presence and amount of CA125 in the biological sample."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising creating a record indicating one or both of the presence and amount of the one or more biomarkers in the biological sample."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising creating a record indicating that the subject should undergo one or more additional diagnostic tests to detect an ovarian cancer if the subject is classified as likely to have an ovarian cancer."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 22, wherein the one or more additional tests comprise a biopsy."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising creating a record indicating that the subject is likely to have ovarian cancer if the subject is classified as likely to have an ovarian cancer."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 21, wherein the record is on a computer readable medium."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising prescribing for the subject a therapy comprising an anti-cancer agent if the amount of the biomarker peptide is different than the non-ovarian cancer reference amount of the biomarker peptide."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["A method for detecting a likelihood of ovarian cancer in a female subject, the method comprising:\n
measuring the amount of at least four biomarkers in a biological sample from the subject using mass spectrometry,\n
wherein the biomarkers are peptides selected from the group consisting of peptides having a mass-to-charge ratio (m/z) signal at m/z 1739.93, 2582.35, 2659.27, and 2989.49, and wherein one or both of a decrease in the amount of the signal at m/z 1739.93 and an increase in the amount of signal at m/z 2582.35, 2659.27, and 2989.49 in the biological sample as compared to a non-ovarian cancer reference amount of the signals indicates that the subject is likely to have ovarian cancer."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["A method for detecting a likelihood of ovarian cancer in a female subject, the method comprising:\n
measuring the amount of at least five biomarkers in a biological sample from the subject,\n
wherein the biomarkers comprise SEQ ID NOS: 2, 3, 4, 5, and 6, and wherein one or both of a decrease in the amount of SEQ ID NO: 2 and 4, and an increase in the amount of SEQ ID NOS: 3, 5, and 6, in the biological sample as compared to a non-ovarian cancer reference amount of the biomarkers indicates that the subject is likely to have ovarian cancer."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["A method for detecting a likelihood of ovarian cancer in a female subject, the method comprising:\n
measuring the amount of at least seven biomarkers in a biological sample from the subject,\n
wherein the biomarkers comprise an amino acid sequence comprising SEQ ID NOS: 8, 15, 2, 3, 4, 5, and 6, and wherein one or both of a decrease in the amount of SEQ ID NOS: 8, 2, and 4, and an increase in the amount of SEQ ID NOS: 15, 3, 5, and 6, in the biological sample as compared to a non-ovarian cancer reference amount of the biomarkers indicates that the subject is likely to have ovarian cancer."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["A method for detecting a likelihood of ovarian cancer in a female subject, the method comprising:\n
measuring the amount of at least nine biomarkers in a biological sample from the subject, wherein the biomarkers comprise SEQ ID NOS: 9, 8, 12, 10, 11, 15, 22, 13, and 20, and wherein one or both of a decrease in the amount of SEQ ID NOS: 9, 8, 12, 10, and 11, and an increase in the amount of SEQ ID NOS: 15, 22, 13, and 20, in the biological sample as compared to a non-ovarian cancer reference amount of the biomarkers indicates that the subject is likely to have ovarian cancer."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating an ovarian cancer in a female subject, the method comprising:\n
determining the amount of a peptide selected from SEQ ID NOs: 1-6, 8-13, 15, 20, and 22 in a biological sample from the subject; and\n
administering to the subject a therapy comprising an effective amount of an anti-cancer agent if in the biological sample it has been determined that:\n
(a) the amount of a peptide selected from SEQ ID NOs: 1, 2, 4, and 8-12 is decreased in the biological sample as compared to a non-ovarian cancer reference amount of the biomarker; or\n
(b) the amount of a peptide selected from SEQ ID NOs: 3, 5, 6, 13, 15, 20, and 22 is increased in biological sample as compared to a non-ovarian cancer reference amount of the biomarker."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["A method for selecting a therapy for a female subject, the method comprising:\n
determining the amount of a biomarker peptide in a biological sample from the subject, wherein the biomarker peptide is selected from SEQ ID NOs: 1-6, 8-13, 15, 20, and 22; and\n
selecting for the subject a therapy comprising an anti-cancer agent if in the biological sample from the subject\n
(a) the amount of a peptide selected from SEQ ID NOs: 1, 2, 4, and 8-12 is decreased in the biological sample as compared to a non-ovarian cancer reference amount of the biomarker; or\n
(b) the amount of a peptide selected from SEQ ID NOs: 3, 5, 6, 13, 15, 20, and 22 is increased in biological sample as compared to a non-ovarian cancer reference amount of the biomarker."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein at least one of the biomarkers is the peptide SEQ ID NO: 1."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 31, wherein the biomarker peptide is SEQ ID NO:1."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 32, wherein the biomarker peptide is SEQ ID NO:1."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 31, wherein the biological sample comprises serum."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 32, wherein the biological sample comprises serum."],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein an increase in the amount of a biomarker peptide selected from SEQ ID NOs: 3, 5, 6, 15, 20, and 22 in the biological sample as compared to the non-ovarian cancer reference amount of the biomarker peptide indicates that the subject has an ovarian cancer."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 38, wherein the amount of the biomarker peptide in the biological sample is at least two-fold higher than the non-ovarian cancer reference amount of the biomarker peptide."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein a decrease in the amount of a biomarker peptide selected from SEQ ID NOs: 1, 2, 4, 8, 9, 10, and 12 in the biological sample as compared to the non-ovarian cancer reference amount of the biomarker peptide indicates that the subject has an ovarian cancer."],"number":40,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 40, wherein the amount of the biomarker peptide in the biological sample is at least two-fold lower than the non-ovarian cancer reference amount of the biomarker peptide."],"number":41,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein at least one of the biomarkers consists of a peptide selected from SEQ ID NOs: 1-6, 8-13, 15, 20, and 22."],"number":42,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 32, wherein the biomarker peptide consists of a sequence selected from SEQ ID NOs: 1-6, 8-13, 15, 20, and 22."],"number":43,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 12, wherein the biomarkers comprise peptides having a mass-to-charge ratio (m/z) signal at m/z 1865.02, 1966.91, 1041.68, 2115.05, 1224.68, 2345.19, 1739.93, 1690.94, 1865.01, 2021.11, 1777.97, 3027.57, 2582.35, 3239.55, and 2898.54, and wherein one or both of a decrease in the amount of the signal at m/z 1865.02, 1966.91, 2115.05, 1739.93, 1690.94, 1865.01, 2021.11, and 1777.97, and an increase in the amount of signal at m/z 1041.68, 1224.68, 2345.19, 3027.57, 2582.35, 3239.55, and 2898.54 in the biological sample as compared to a non-ovarian cancer reference amount of the signals indicates that the subject is likely to have ovarian cancer."],"number":44,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 27, wherein the biological sample comprises serum."],"number":45,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 27, further comprising detecting one or both of the presence and amount of CA125 in the biological sample."],"number":46,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the measuring comprises mass spectrometry."],"number":47,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 47, wherein the biomarkers comprise peptides having a mass-to-charge ratio (m/z) signal at m/z 1966.91, 1041.68, 2115.05, 1224.68, and 2345.19, and wherein one or both of a decrease in the amount of the signal at m/z 1966.91 and 2115.05 and an increase in the amount of signal at m/z 1041.68, 1224.68, and 2345.19 in the biological sample as compared to a non-ovarian cancer reference amount of the signals indicates that the subject is likely to have ovarian cancer."],"number":48,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 29, wherein the measuring comprises mass spectrometry."],"number":49,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 49, wherein the biomarkers comprise peptides having a mass-to-charge ratio (m/z) signal at m/z 1739.93, 2582.35, 1966.91, 1041.68, 2115.05, 1224.68, and 2345.19, and wherein one or both of a decrease in the amount of the signal at m/z 1739.93, 1966.91 and 2115.05 and an increase in the amount of signal at m/z 2582.35, 1041.68, 1224.68, and 2345.19 in the biological sample as compared to a non-ovarian cancer reference amount of the signals indicates that the subject is likely to have ovarian cancer."],"number":50,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 30, wherein the measuring comprises mass spectrometry."],"number":51,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 51, wherein the biomarkers comprise peptides having a mass-to-charge ratio (m/z) signal at m/z 1690.94, 1739.93, 1777.97, 1865.01, 2021.11, 2582.35, 2898.54, 3027.57, and 3239.55, and wherein one or both of a decrease in the amount of the signal at m/z 1690.94, 1739.93, 1777.97, 1865.01, and 2021.11, and an increase in the amount of signal at m/z 2582.35, 2898.54, 3027.57, and 3239.55 in the biological sample as compared to a non-ovarian cancer reference amount of the signals indicates that the subject is likely to have ovarian cancer."],"number":52,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 31, wherein the determining comprises mass spectrometry."],"number":53,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 53, wherein the biomarkers comprise peptides having a mass-to-charge ratio (m/z) signal at m/z 1865.02, 1966.91, 1041.68, 2115.05, 1224.68, 2345.19, 1739.93, 1690.94, 1865.01, 2021.11, 1777.97, 3027.57, 2582.35, 3239.55, and 2898.54, and administering to the subject a therapy comprising an effective amount of an anti-cancer agent if the amount of the signal at m/z 1865.02, 1966.91, 2115.05, 1739.93, 1690.94, 1865.01, 2021.11, and 1777.97 is decreased or the amount of signal at m/z 1041.68, 1224.68, 2345.19, 3027.57, 2582.35, 3239.55, and 2898.54 is increased in the biological sample as compared to a non-ovarian cancer reference amount of the signals."],"number":54,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 32, wherein the determining comprises mass spectrometry."],"number":55,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 55, wherein the biomarkers comprise peptides having a mass-to-charge ratio (m/z) signal at m/z 1865.02, 1966.91, 1041.68, 2115.05, 1224.68, 2345.19, 1739.93, 1690.94, 1865.01, 2021.11, 1777.97, 3027.57, 2582.35, 3239.55, and 2898.54, and selecting for the subject a therapy comprising an anti-cancer agent if the amount of the signal at m/z 1865.02, 1966.91, 2115.05, 1739.93, 1690.94, 1865.01, 2021.11, and 1777.97 is decreased or the amount of signal at m/z 1041.68, 1224.68, 2345.19, 3027.57, 2582.35, 3239.55, and 2898.54 is increased in the biological sample as compared to a non-ovarian cancer reference amount of the signals."],"number":56,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}